CDKN2A and pancreatic neoplasm: On the other hand, the American Gastroenterological Association (AGA) Institute Clinical Practice recommends screening (1) individuals with germline mutations in LKB/STK11 (Peutz–Jeghers syndrome), CDKN2A (FAMMM), and PRSS1 (hereditary pancreatitis) regardless of family history; (2) individuals with germline mutations in BRCA1, BRCA2, PALB2, ATM, or MLH1/MSH2/MSH6 (Lynch syndrome) and at least one affected FDR; and (3) FDRs of patients with pancreatic cancer with at least two affected genetically related relatives [16].